The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
A possible role for humoral immunity in the pathogenesis of Parkinson's disease
Abstract
The pathogenesis of idiopathic Parkinson's disease is unknown, but nigral degeneration and depigmentation are associated with microglial inflammation and anti-inflammatory medications appear to protect against the disease. The possibility that humoral immunity may play a role in initiating or regulating the inflammation has been suggested by experimental studies triggering dopamine cell death using a variety of transfer strategies and the observation of CD8+ T lymphocytes and complement in the nigra in Parkinson's disease. We analysed the association between degeneration and humoral immune markers in brain tissue of patients with idiopathic (n = 13) or genetic (n = 2 with alpha-synuclein and n = 1 with parkin mutations) Parkinson's disease and controls without neurological disease (n = 12) to determine the humoral immune involvement in Parkinson's disease. Formalin-fixed tissue samples from the substantia nigra and primary visual cortex for comparison were stained for alpha-synuclein, major histocompatibility complex II (HLA), immunoglobulin M (IgM), immunoglobulin G (IgG), IgG subclasses 1-4 and IgG receptors FcgammaR I-III. Antigen retrieval and both single immunoperoxidase and double immunofluorescence procedures were employed to determine the cell types involved and their pattern and semiquantitative densities. Significant dopamine neuron loss occurred in all patients with Parkinson's disease, negatively correlating with disease duration (r = -0.76, P = 0.002). Although all patients had increased inflammatory HLA immunopositive microglia, the degree of inflammation was similar throughout the disease (r = 0.08, P = 0.82). All patients with Parkinson's disease had IgG binding on dopamine neurons but not IgM binding. Lewy bodies were strongly immunolabelled with IgG. A mean 30 +/- 12% of dopamine nigral neurons were immunoreactive for IgG in Parkinson's disease with the proportion of IgG immunopositive neurons negatively correlating with the degree of cell loss in the substantia nigra (r = -0.67, P < 0.0001) and positively correlating with the number of HLA immunopositive microglia (r = 0.51, P = 0.01). Most neuronal IgG was the IgG1 subclass with some IgG3 and less IgG2 also found in the damaged substantia nigra. The high affinity activating IgG receptor, FcgammaRI, was expressed on nearby activated microglia. The low affinity activating IgG receptor, FcgammaRIII was expressed on cells morphologically resembling lymphocytes, whereas immunoreactivity for the inhibitory IgG receptor FcgammaRII was absent in all cases. This pattern of humoral immune reactivity is consistent with an immune activation of microglia leading to the targeting of dopamine nigral neurons for destruction in both idiopathic and genetic cases of Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Aloisi, F. (2001) · Glia · doi:10.1002/glia.1106 · Cited by 1,280
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 2×
“Direct inhibition of microglial activation (He et al., 2001; Liu et al., 2000; Wu et al., 2002) or therapeutic immunization using adoptive transfer of immune cells (Benner et al., 2004; Boska et al., 2005) is neuroprotective in these models.”
MethodKim, W.-G., Mohney, R. P., Wilson, B., Jeohn, G.-H., Liu, B., & Hong, J.-S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06309.2000 · Cited by 878
Microglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 843
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791 · cited 1×
“The degree of cell loss and reactive microgliosis were similar to those previously described for similar case types (Fearnley and Lees, 1991; Imamura et al., 2003).”
ResultBlood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
Cited by
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446
Inflammation and immune dysfunction in Parkinson disease
Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00684-6 · Cited by 1,382
Microglia development and function
Nayak, D., Roth, T. L., & McGavern, D. B. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120240 · Cited by 1,154
Autophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039
Calabresi, P., Mechelli, A., Natale, G., Volpicelli-Daley, L., Di Lazzaro, G., & Ghiglieri, V. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05672-9 · Cited by 817
Hamza, T. H., Zabetian, C. P., Tenesa, A., Laederach, A., Montimurro, J., Yearout, D., Kay, D. M., Doheny, K. F., Paschall, J., Pugh, E., et al. (2010) · Nature Genetics · doi:10.1038/ng.642 · Cited by 784
Wakabayashi, K., Tanji, K., Mori, F., & Takahashi, H. (2007) · Neuropathology · doi:10.1111/j.1440-1789.2007.00803.x · Cited by 516
Sex differences in Parkinson’s disease
Gillies, G. E., Pienaar, I. S., Vohra, S., & Qamhawi, Z. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.02.002 · Cited by 489
The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders
Wakabayashi, K., Tanji, K., Odagiri, S., Miki, Y., Mori, F., & Takahashi, H. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8280-y · Cited by 479
Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease
Gelders, G., Baekelandt, V., & Van der Perren, A. (2018) · Journal of Immunology Research · doi:10.1155/2018/4784268 · Cited by 430
Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy
Rigau, V., Morin, M., Rousset, M.-C., de Bock, F., Lebrun, A., Coubes, P., Picot, M.-C., Baldy-Moulinier, M., Bockaert, J., Crespel, A., et al. (2007) · Brain · doi:10.1093/brain/awm118 · Cited by 429
Glia: Initiators and progressors of pathology in Parkinson's disease
Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 424
Self-citationNeuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., & Lee Mosley, R. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507296 · Cited by 420
Harms, A. S., Cao, S., Rowse, A. L., Thome, A. D., Li, X., Mangieri, L. R., Cron, R. Q., Shacka, J. J., Raman, C., & Standaert, D. G. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5610-12.2013 · Cited by 406
Parkinson's disease: Autoimmunity and neuroinflammation
De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M. I., Gallo, A., Conte, M., Rosato, C., Ciniglio Appiani, M., & de Vincentiis, M. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.022 · Cited by 389
Systems medicine: the future of medical genomics and healthcare
Auffray, C., Chen, Z., & Hood, L. (2009) · Genome Medicine · doi:10.1186/gm2 · Cited by 387
Theodore, S., Cao, S., McLean, P. J., & Standaert, D. G. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818e5e99 · Cited by 367
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Marogianni, C., Sokratous, M., Dardiotis, E., Hadjigeorgiou, G. M., Bogdanos, D., & Xiromerisiou, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228421 · Cited by 366
The relevance of iron in the pathogenesis of Parkinson’s disease
Sian‐Hülsmann, J., Mandel, S., Youdim, M. B. H., & Riederer, P. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07132.x · Cited by 352
González, H., Elgueta, D., Montoya, A., & Pacheco, R. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.07.012 · Cited by 352
B cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
The Role of Innate and Adaptive Immunity in Parkinson's Disease
Kannarkat, G. T., Boss, J. M., & Tansey, M. G. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130250 · Cited by 324
“of pigmented DA neurons [125].”
The immunoregulatory role of dopamine: An update
Sarkar, C., Basu, B., Chakroborty, D., Dasgupta, P. S., & Basu, S. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.10.015 · Cited by 323
CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease
Williams, G. P., Schonhoff, A. M., Jurkuvenaite, A., Gallups, N. J., Standaert, D. G., & Harms, A. S. (2021) · Brain · doi:10.1093/brain/awab103 · Cited by 306
The Genetics of Parkinson Disease
Bekris, L. M., Mata, I. F., & Zabetian, C. P. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383572 · Cited by 301
Recent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274
“The pattern of humoral immune reactivity is consistent with an immune activation of microglia leading to the targeting of DA nigral neurons for the destruction in both idiopathic and genetic cases of PD (Gao et al. 2008; Orr et al. 2005).”
BackgroundPeriphery and brain, innate and adaptive immunity in Parkinson’s disease
Harms, A. S., Ferreira, S. A., & Romero-Ramos, M. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02268-5 · Cited by 272
Microglia and neuroprotection: From in vitro studies to therapeutic applications
Polazzi, E., & Monti, B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.009 · Cited by 262
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
Harms, A. S., Thome, A. D., Yan, Z., Schonhoff, A. M., Williams, G. P., Li, X., Liu, Y., Qin, H., Benveniste, E. N., & Standaert, D. G. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.11.010 · Cited by 236
Parkinson’s disease as a result of aging
Rodriguez, M., Rodriguez‐Sabate, C., Morales, I., Sanchez, A., & Sabate, M. (2015) · Aging Cell · doi:10.1111/acel.12312 · Cited by 214
Congdon, E. E., Gu, J., Sait, H. B. R., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.491001 · Cited by 195
“Early reports demonstrated that A plaques and activated microglia in AD patients were immunoreactive for antibodies against Fc I, II, and III (37) with similar results also seen in Parkinson disease (38, 39).”
ResultInflammation in Parkinson’s disease: role of glucocorticoids
Herrero, M.-T., Estrada, C., Maatouk, L., & Vyas, S. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00032 · Cited by 175
“…observed in SN and striatum of PD (Hunot et al., 1996) suggests that the toxicity originating both from cytokines/chemokines and inflammation-derived oxidative stress could contribute to dopaminergic neuronal degeneration and progression of the disease (Orr et al., 2005; Wilms et al., 2007).”
BackgroundYanamandra, K., Gruden, M. A., Casaite, V., Meskys, R., Forsgren, L., & Morozova-Roche, L. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018513 · Cited by 171
Aging and Neurodegenerative Disease: Is the Adaptive Immune System a Friend or Foe?
Mayne, K., White, J. A., McMurran, C. E., Rivera, F. J., & de la Fuente, A. G. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.572090 · Cited by 167
Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts
Fellner, L., Jellinger, K. A., Wenning, G. K., & Stefanova, N. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0833-z · Cited by 162
“In DLB, a positive correlation between LBs and microglial activation in different brain regions has been demonstrated [137].”
BackgroundInfluentialGlycosphingolipids and Neuroinflammation in Parkinson’s Disease
Belarbi, K., Cuvelier, E., Bonte, M.-A., Desplanque, M., Gressier, B., Devos, D., & Chartier-Harlin, M.-C. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00408-1 · Cited by 155
New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease
Fuller, J. P., Stavenhagen, J. B., & Teeling, J. L. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00235 · Cited by 154
The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases
Zang, X., Chen, S., Zhu, J., Ma, J., & Zhai, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.872134 · Cited by 139
The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?
Doty, K. R., Guillot-Sestier, M.-V., & Town, T. (2015) · Brain Research · doi:10.1016/j.brainres.2014.09.008 · Cited by 104
The Role of Anti-Inflammatory Agents in Parkinson???s Disease
McGeer, E. G., & McGeer, P. L. (2007) · CNS Drugs · doi:10.2165/00023210-200721100-00001 · Cited by 95
Neuroinflammation in dementia with Lewy bodies: a human post-mortem study
Amin, J., Holmes, C., Dorey, R. B., Tommasino, E., Casal, Y. R., Williams, D. M., Dupuy, C., Nicoll, J. A. R., & Boche, D. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00954-8 · Cited by 89
The link between neuroinflammation and the neurovascular unit in synucleinopathies
Wang, Q., Zheng, J., Pettersson, S., Reynolds, R., & Tan, E.-K. (2023) · Science Advances · doi:10.1126/sciadv.abq1141 · Cited by 81
Jeon, M.-T., Kim, K.-S., Kim, E. S., Lee, S., Kim, J., Hoe, H.-S., & Kim, D.-G. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101333 · Cited by 76
Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease
Kasen, A., Houck, C., Burmeister, A. R., Sha, Q., Brundin, L., & Brundin, P. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105654 · Cited by 78
Regulation of the neurodegenerative process associated to Parkinson's disease by CD4+ T-cells
González, H., Contreras, F., & Pacheco, R. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9618-9 · Cited by 70
Akhtar, R. S., Licata, J. P., Luk, K. C., Shaw, L. M., Trojanowski, J. Q., & Lee, V. M. ‐. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14330 · Cited by 60
Scheffold, A., Holtman, I. R., Dieni, S., Brouwer, N., Katz, S.-F., Jebaraj, B. M. C., Kahle, P. J., Hengerer, B., Lechel, A., Stilgenbauer, S., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0364-x · Cited by 53
“It is very well known that microglia are activated in all synucleopathies including humans with PD [62 – 64]. inflammatory cytokines in microglia in PD pathology.”
BackgroundPotential importance of B cells in aging and aging-associated neurodegenerative diseases
Biragyn, A., Aliseychik, M., & Rogaev, E. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-016-0615-8 · Cited by 25
Aspects of innate immunity and Parkinson's disease
Huang, Y., & Halliday, G. M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00033 · Cited by 22
Self-citationResearch Progress on the Relationship between Parkinson's Disease and REM Sleep Behavior Disorder
Zhou, Y., Liu, X., & Xu, B. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2309166 · Cited by 13
Metadata
- Authors
- Orr, C. F., Rowe, D. B., Mizuno, Y., Mori, H., & Halliday, G. M.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-10-11
- Volume
- 128
- Issue
- 11
- Pages
- 2665-2674
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2165339984
- Cited by
- 350
- References
- 50
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.